GLP-1 (Glucagon-Like Peptide-1)

FDA-approved context Weight Loss & Metabolism 3 sources

Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying. Research has led to the development of GLP-1 receptor agonists, which are widely used for managing type 2 diabetes and obesity due to their profound effects on blood sugar regulation and appetite suppression.

01Dosing reference

Amount

Native GLP-1 is not dosed due to rapid degradation; synthetic analogs follow specific clinical guidelines

Frequency

Varies by specific formulation (daily or weekly)

Cycle

Continuous use for chronic management

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-1 Receptor Activation

Binds to and activates the GLP-1 receptor on pancreatic beta cells and in the central nervous system.

Incretin Effect & Gastric Slowing

Enhances glucose-dependent insulin secretion, suppresses glucagon, and delays gastric emptying.

Metabolic & Appetite Regulation

Improves glycemic control and promotes satiety, leading to reduced food intake and weight loss.

03Human evidence

Significant reduction in HbA1c and fasting plasma glucose in patients with type 2 diabetes.

Extensive clinical trials on GLP-1 receptor agonists (e.g., exenatide, liraglutide, semaglutide) involving thousands of participants.

Substantial dose-dependent weight loss in obese and overweight individuals.

Large-scale randomized controlled trials demonstrating sustained weight reduction with long-acting GLP-1 analogs.

04Preclinical evidence

Promotion of pancreatic beta-cell proliferation and survival.

Observed in rodent models, suggesting potential disease-modifying effects in diabetes.

Neuroprotective effects and reduction of neuroinflammation.

Animal models of Alzheimer's and Parkinson's diseases, indicating potential central nervous system benefits.

05What is known vs. unknown

Reasonably established

Stimulates insulin release only when blood glucose levels are elevated, minimizing hypoglycemia risk.
Slows gastric emptying, which contributes to increased feelings of fullness and reduced appetite.
Native GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the DPP-4 enzyme.
Synthetic GLP-1 receptor agonists are modified to resist DPP-4 degradation, allowing for daily or weekly dosing.

Unknowns & limits

Long-term effects of sustained GLP-1 receptor overactivation on pancreatic and thyroid tissues remain an area of ongoing surveillance.
The exact mechanisms underlying the rare but reported cases of gastroparesis and pancreatitis require further elucidation.

06Safety & regulatory context

Regulatory statusNative GLP-1 is rapidly degraded and not used therapeutically. However, GLP-1 receptor agonists (such as semaglutide, liraglutide, and dulaglutide) are FDA-approved for the treatment of type 2 diabetes and chronic weight management. Common side effects include gastrointestinal disturbances like nausea, vomiting, diarrhea, and constipation, which often subside over time. There is a potential risk of pancreatitis and a boxed warning for thyroid C-cell tumors based on rodent studies, making them contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

07Compared with GIP (Glucose-Dependent Insulinotropic Polypeptide)

GLP-1 (Glucagon-Like Peptide-1) vs. GIP (Glucose-Dependent Insulinotropic Polypeptide)

Key difference

While both are incretin hormones, GLP-1 suppresses glucagon secretion and significantly slows gastric emptying, whereas GIP stimulates glucagon under hypoglycemic conditions and has less effect on gastric motility.

When researchers discuss each

Researchers discuss GLP-1 when focusing on appetite suppression and robust glycemic control, and GIP when exploring synergistic effects in dual-agonists (like tirzepatide) for enhanced metabolic benefits.

08Glossary

Incretin

A type of metabolic hormone that stimulates a decrease in blood glucose levels by increasing the amount of insulin released from the pancreas.

DPP-4 (Dipeptidyl Peptidase-4)

An enzyme that rapidly breaks down incretin hormones like GLP-1 and GIP in the body.

Gastric Emptying

The process by which food leaves the stomach and enters the small intestine.

09Knowledge check

Q1Why is native GLP-1 not typically used as a therapeutic drug?

Q2Which of the following is a primary mechanism by which GLP-1 promotes weight loss?

Q3Which of the following describes a documented limitation or ongoing uncertainty about GLP-1 receptor agonist therapies in the dossier?

Q4When researchers compare GLP-1 to GIP, which of these differences matches the dossier's stated comparison context?

Q5Which statement best reflects the safety or regulatory information about GLP-1 receptor agonists given in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.